"There should have been a better negotiation and it shouldn't have been forced. What started the price controversy was the unilateral price fixing by the government at Rs 150 per dose. Initially the company didn't have a problem with the pricing. What shocked them was the downward revising by the government," says Kiran Mazumdar Shaw, Executive Chairperson, Biocon, to NDTV.
